|
시장보고서
상품코드
1402732
중남미의 줄기세포 치료 시장 예측(-2028년) : 지역별 분석 - 유형별, 치료별, 용도별, 최종사용자별South & Central America Stem Cell Therapy Market Forecast to 2028 - Regional Analysis - by Type, Treatment, Application, and End User |
||||||
중남미 줄기세포 치료는 2022년 7,516만 달러에서 2028년 1억 3,930만 달러로 성장할 것으로 예상되며, 2022년부터 2028년까지 CAGR은 10.8%로 추정됩니다.
재생의료에서 유도만능줄기세포 사용으로 중남미 줄기세포 치료 시장 성장 견인
Frontiers Media S.A.의 2023년 보고서에 따르면, 유도만능줄기세포(iPSC)의 발전은 주로 질병 모델링, 재생의료, 신약개발/약물 세포독성 연구 등 연구 및 임상연구를 목적으로 하는 iPSC를 통해 치료제 연구의 새로운 장을 열었다고 합니다. 예를 들어, iPSC는 분화된 체세포를 만능줄기세포로 전환하여 성체 조직의 다양한 세포종을 생성하는 데 사용할 수 있으며, iPS 세포는 부상 및 퇴행성 질환을 치료하기 위해 환자에게 이식하는 조직 특이적 세포를 재생하는 데 널리 사용되고 있습니다. 저분자 스크리닝과 안전성 평가를 위한 독성시험을 포함한 신약개발과 같은 연구는 iPSC를 기반으로 한 긍정적인 결과를 성공적으로 공개하고 있습니다. 앞서 언급한 요인들은 향후 몇 년 동안 중남미 줄기세포 치료 시장에 진출하는 기업들에게 유리한 성장 기회를 제공할 것으로 예상됩니다.
중남미 줄기세포 치료의 개요
브라질 정부와 의료 당국은 줄기세포 치료의 인지도와 노출을 높이기 위해 건설적인 전략을 시행하고 있습니다. 예를 들어, 당국은 국제적인 관심을 끌기 위해 국내 임상시험 실시에 주력하고 있습니다. 예를 들어, clinicaltrials.gov에 따르면, 2016년 브라질에서 약 27건의 줄기세포 연구가 진행되었으며, 이는 전 세계 줄기세포 연구의 1.7%를 차지하는 것으로 추정됩니다. 또한, 브라질은 줄기세포 분야 진출 초기에 약 500만 달러가 줄기세포 연구에 배정됐습니다. 브라질의 인식이 높아짐에 따라 줄기세포 시장의 혁신과 발견의 성장에 박차를 가하고 있습니다. 예를 들어, 2017년 브라질의 스타트업 R-Crio는 젖니 하나에서 약 700만 개의 줄기세포를 생성하는 방법을 발견했습니다. 이러한 요인들은 예측 기간 동안 브라질 줄기세포 치료 시장의 성장을 촉진할 것으로 보입니다.
중남미 줄기세포 치료 매출 및 2028년까지의 예측(금액)
중남미 줄기세포 치료의 세분화
중남미 줄기세포 치료는 유형, 치료, 용도, 최종사용자, 국가별로 세분화됩니다.
유형별로 중남미 줄기세포 치료는 성체줄기세포 치료, 배아줄기세포 치료, 유도만능줄기세포 치료, 기타 줄기세포 치료로 구분되며, 2022년에는 성체줄기세포 치료 부문이 중남미 줄기세포 치료에서 가장 큰 점유율을 차지했습니다. 성체줄기세포 치료 부문은 조혈 줄기세포 치료, 제대혈 줄기세포 치료, 신경 줄기세포 치료, 중간엽 줄기세포 치료로 세분화됩니다.
치료에 따라 중남미 줄기세포 치료는 동종 이식과 자가 이식으로 나뉘며, 2022년에는 동종 이식이 중남미 줄기세포 치료에서 큰 비중을 차지했습니다.
용도별로 중남미 줄기세포 치료는 근골격계, 피부과, 심장병학, 신약개발, 기타 용도로 구분되며, 2022년에는 근골격계가 중남미 줄기세포 치료에서 가장 큰 점유율을 차지했습니다.
최종사용자별로 중남미 줄기세포 치료는 병원 및 전문 클리닉과 학술 및 연구기관으로 구분되며, 2022년에는 학술 및 연구기관 부문이 남미 줄기세포 치료에서 더 큰 점유율을 기록했습니다.
국가별로는 중남미 줄기세포 치료는 브라질, 아르헨티나, 기타 중남미로 구분되며, 2022년 브라질이 중남미 줄기세포 치료에서 가장 큰 점유율을 차지했습니다.
목차
제1장 서론
제2장 중남미의 줄기세포 치료 시장 - 요점
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 중남미의 줄기세포 치료 시장 - 시장 상황
- 중남미의 PEST 분석
- 전문가의 견해
제5장 중남미의 줄기세포 치료 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 효과적인 질환 관리를 위한 줄기세포 치료에 관한 조사 활동의 증가
- 암 유병률 증가
- 시장 성장 억제요인
- 승인된 치료의 고비용
- 시장 기회
- 재생의료의 유도만능줄기세포 이용
- 향후 동향
- 연구 활동과 제품 혁신
- 영향 분석
제6장 줄기세포 치료 시장 : 중남미 분석
- 중남미의 줄기세포 치료 시장 매출과 예측 분석
제7장 중남미의 줄기세포 치료 시장 - 2028년까지 매출과 예측 : 유형별
- 중남미의 줄기세포 치료 시장 매출 점유율 : 유형별, 2021년·2028년(%)
- 성체줄기세포 치료
- 배아줄기세포 치료
- 유도만능줄기세포 치료
- 기타
제8장 중남미의 줄기세포 치료 시장 분석과 2028년까지 예측 : 치료별
- 중남미의 줄기세포 치료 시장 매출 점유율 : 치료별, 2021년·2028년(%)
- 동종이식
- 자가이식
제9장 중남미의 줄기세포 치료 시장 분석과 2028년까지 예측 : 용도별
- 중남미의 줄기세포 치료 시장 매출 점유율 : 용도별, 2021년·2028년(%)
- 근골격계
- 피부과학
- 심장병학
- Drug Discovery & Development
- 기타
제10장 중남미의 줄기세포 치료 시장 - 2028년까지 매출과 예측 : 최종사용자별
- 중남미의 줄기세포 치료 시장 매출 점유율 : 최종사용자별, 2021년·2028년(%)
- 학술·연구기관
- 병원·전문 클리닉
제11장 중남미의 줄기세포 치료 시장 - 2028년까지 매출과 예측 : 국가별 분석
- 중남미
- 브라질
- 아르헨티나
- 기타 중남미
제12장 중남미의 줄기세포 치료 시장 - 업계 상황
- 유기적 발전
- 무기적 발전
제13장 기업 개요
- TiGenix NV(Takeda Pharmaceutical Company Limited)
- NuVasive Inc
- Lonza Group AG
- Smith & Nephew Plc
제14장 부록
ksm 24.01.15The South & Central America stem cell therapy is expected to grow from US$ 75.16 million in 2022 to US$ 139.30 million by 2028. It is estimated to grow at a CAGR of 10.8% from 2022 to 2028.
Use of Induced Pluripotent Stem Cells in Regenerative Medicines Drives South & Central America Stem Cell Therapy Market
Per the Frontiers Media S.A. 2023 report, progress in the field of induced pluripotent stem cells (iPSCs) has opened a new gateway for research in therapeutics. iPSCs are mainly intended for research and clinical studies such as disease modeling, regenerative medicine, and drug discovery/drug cytotoxicity studies. For example, iPSCs can be used to convert differentiated somatic cells to multipotent stem cells to generate different cell types of adult tissues. Thus, iPSCs have shown promising results in regenerative medicine, particularly for replacing diseased or injured cells. iPSCs are widely used to regenerate tissue-specific cells for transplantation in patients for treating injuries and degenerative diseases. Studies such as drug discovery involving screening of small molecules and toxicity testing for safety assessment have been successfully disclosed positive iPSCs-based results. The aforementioned factors are expected to offer lucrative growth opportunities to companies in the South & Central America stem cell therapy market in the coming years.
South & Central America Stem Cell Therapy Overview
The government and healthcare authorities in Brazil are implementing constructive strategies to increase the awareness and exposure of stem cell therapies in the countries. For example, providing international exposure, the authorities are focusing on conducting clinical trials in the country. For instance, according to clinicaltrials.gov, in 2016, around 27 stem cell studies were being conducted in the country, which accounted for an estimated 1.7% of all the stem cell studies across the globe. Also, the country allotted around US$ 5.0 Mn for stem cell research at the starting beginning of the entry in the stem cell domain. Increasing awareness in the country is fueling the growth of innovations and discoveries in the stem cell market. For instance, in 2017, R-Crio, a Brazil-based startup, discovered a way to produce around 7 million stem cells from a single baby tooth. These factors are likely to drive the growth of the Brazil stem cell therapy market during the forecast period.
South & Central America Stem Cell Therapy Revenue and Forecast to 2028 (US$ Million)
South & Central America Stem Cell Therapy Segmentation
The South & Central America stem cell therapy is segmented into type, treatment, application, end user, and country.
Based on type, the South & Central America stem cell therapy is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. In 2022, the adult stem cell therapy segment registered the largest share in the South & Central America stem cell therapy. The adult stem cell therapy segments is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.
Based on treatment, the South & Central America stem cell therapy is bifurcated into allogeneic and autologous. In 2022, the allogeneic segment registered a larger share in the South & Central America stem cell therapy.
Based on application, the South & Central America stem cell therapy is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. In 2022, the musculoskeletal segment registered the largest share in the South & Central America stem cell therapy.
Based on end user, the South & Central America stem cell therapy is bifurcated into hospitals & specialty clinics and academic & research institutes. In 2022, the academic & research institutes segment registered a larger share in the South & Central America stem cell therapy.
Based on country, the South & Central America stem cell therapy is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil segment registered the largest share in the South & Central America stem cell therapy.
Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited) are some of the leading companies operating in the South & Central America stem cell therapy.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America stem cell therapy market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central America stem cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the stem cell therapy market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table Of Contents
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 South & Central America Stem Cell Therapy Market - By Type
- 1.3.2 South & Central America Stem Cell Therapy Market - By Treatment
- 1.3.3 South & Central America Stem Cell Therapy Market - By Application
- 1.3.4 South & Central America Stem Cell Therapy Market - By End User
- 1.3.5 South & Central America Stem Cell Therapy Market - By Country
2. South & Central America Stem Cell Therapy Market - Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. South & Central America Stem Cell Therapy Market- Market Landscape
- 4.1 Overview
- 4.2 South & Central America PEST Analysis
- 4.3 Experts Opinion
5. South & Central America Stem Cell Therapy Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Increasing Research Activities Related to Stem Cell Therapy for Effective Disease Management
- 5.1.2 Growing Prevalence of Cancer
- 5.2 Market Restraints
- 5.2.1 High Cost of Approved Treatments
- 5.3 Market Opportunities
- 5.3.1 Use of Induced Pluripotent Stem Cells in Regenerative Medicines
- 5.4 Future Trends
- 5.4.1 Research Activities and Product Innovations
- 5.5 Impact Analysis
6. Stem Cell Therapy Market - South & Central America Analysis
- 6.1 South & Central America Stem Cell Therapy Market Revenue Forecast and Analysis
7. South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 - by Type
- 7.1 Overview
- 7.2 South & Central America Stem Cell Therapy Market Revenue Share, by Type 2021 & 2028 (%)
- 7.3 Adult Stem Cell Therapy
- 7.3.1 Overview
- 7.3.2 Adult Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.3 Hematopoietic Stem Cell Therapy
- 7.3.3.1 Overview
- 7.3.3.2 Hematopoietic Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.4 Umbilical Cord Stem Cell Therapy
- 7.3.4.1 Overview
- 7.3.4.2 Umbilical Cord Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.5 Neuronal Stem Cell Therapy
- 7.3.5.1 Overview
- 7.3.5.2 Neuronal Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.6 Mesenchymal Stem Cell
- 7.3.6.1 Overview
- 7.3.6.2 Mesenchymal Stem Cell: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Embryonic Stem Cell Therapy
- 7.4.1 Overview
- 7.4.2 Embryonic Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5 Induced Pluripotent Stem Cell Therapy
- 7.5.1 Overview
- 7.5.2 Induced Pluripotent Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 7.6 Other Stem Cell Therapy
- 7.6.1 Overview
- 7.6.2 Other Stem Cell Therapy: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Stem Cell Therapy Market Analysis and Forecasts to 2028 - by Treatment
- 8.1 Overview
- 8.2 South & Central America Stem Cell Therapy Market, by Treatment 2021 & 2028 (%)
- 8.3 Allogeneic
- 8.3.1 Overview
- 8.3.2 Allogeneic: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Autologous
- 8.4.1 Overview
- 8.4.2 Autologous: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Stem Cell Therapy Market Analysis and Forecasts to 2028 - by Application
- 9.1 Overview
- 9.2 South & Central America Stem Cell Therapy Market, by Application 2021 & 2028 (%)
- 9.3 Musculoskeletal
- 9.3.1 Overview
- 9.3.2 Musculoskeletal: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Dermatology
- 9.4.1 Overview
- 9.4.2 Dermatology: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 9.5 Cardiology
- 9.5.1 Overview
- 9.5.2 Cardiology: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 9.6 Drug Discovery and Development
- 9.6.1 Overview
- 9.6.2 Drug Discovery and Development: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 9.7 Other Applications
- 9.7.1 Overview
- 9.7.2 Other Applications: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 - by End User
- 10.1 Overview
- 10.2 South & Central America Stem Cell Therapy Market Revenue Share, by End User 2021 & 2028 (%)
- 10.3 Academic & Research Institutes
- 10.3.1 Overview
- 10.3.2 Academic & Research Institutes: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
- 10.4 Hospitals & Specialty Clinics
- 10.4.1 Overview
- 10.4.2 Hospitals & Specialty Clinics: South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 (US$ Million)
11. South & Central America Stem Cell Therapy Market - Revenue and Forecast to 2028 - Country Analysis
- 11.1 Overview
- 11.1.1 South and Central America: Stem Cell Therapy Market, by Country, 2021 & 2028(%)
- 11.1.1.1 Brazil: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.1.1 Brazil: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.1.2 Brazil: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
- 11.1.1.1.2.1 Brazil: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
- 11.1.1.1.3 Brazil: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
- 11.1.1.1.4 Brazil: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
- 11.1.1.1.5 Brazil: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
- 11.1.1.2 Argentina: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.2.1 Argentina: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.2.2 Argentina: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
- 11.1.1.2.2.1 Argentina: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
- 11.1.1.2.3 Argentina: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
- 11.1.1.2.4 Argentina: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
- 11.1.1.2.5 Argentina: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
- 11.1.1.3 Rest of South and Central America: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.3.1 Rest of South and Central America: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1.3.2 Rest of South and Central America: Stem Cell Therapy Market, by Type, 2019-2028 (USD Million)
- 11.1.1.3.2.1 Rest of South and Central America: Stem Cell Therapy Market, by Adult Stem Cell Therapy, 2019-2028 (USD Million)
- 11.1.1.3.3 Rest of South and Central America: Stem Cell Therapy Market, by Treatment, 2019-2028 (USD Million)
- 11.1.1.3.4 Rest of South and Central America: Stem Cell Therapy Market, by Application, 2019-2028 (USD Million)
- 11.1.1.3.5 Rest of South and Central America: Stem Cell Therapy Market, by End User , 2019-2028 (USD Million)
- 11.1.1.1 Brazil: Stem Cell Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.1.1 South and Central America: Stem Cell Therapy Market, by Country, 2021 & 2028(%)
12. South & Central America Stem Cell Therapy Market-Industry Landscape
- 12.1 Overview
- 12.2 Organic Developments
- 12.2.1 Overview
- 12.3 Inorganic Developments
- 12.3.1 Overview
13. Company Profiles
- 13.1 TiGenix NV (Takeda Pharmaceutical Company Limited)
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 NuVasive Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Lonza Group AG
- 13.3.1 Business Description
- 13.3.2 Products and Services
- 13.3.3 Financial Overview
- 13.3.4 SWOT Analysis
- 13.3.5 Key Developments
- 13.4 Smith & Nephew Plc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms
